image sourced from original article at Dr Reddy's Laboratories has received approval from Health Canada to market its generic semaglutide injection, becoming the first company to secure authorization for a generic version of the medicine in the country. The approval covers 2 milligram and 4 milligram per pen presentations at a strength of 1.34 milligram per millilitre, and was granted ahead of the regulator's target review date.
The company said it is preparing to launch the product in Canada and highlighted the approval as a demonstration of its expertise in complex generic and peptide based medicines. The active pharmaceutical ingredient is being manufactured in house, while the finished product is being produced in partnership with OneSource Specialty Pharma.
Semaglutide is a once weekly treatment for adults with type 2 diabetes that helps improve blood sugar control alongside diet and exercise. In Canada, about 3.9 million people live with diagnosed diabetes, and more than 6 percent of adults are estimated to have prediabetes, underscoring the potential demand for the medicine.
